Galectin Therapeutics Inc. is one of the 15 Best Biotech Penny Stocks to Invest in Right Now, with a focus on developing therapies targeting galectin proteins. Their lead candidate, belapectin, has shown promising results in reducing varices development and improving liver stiffness in chronic liver diseases like MASH cirrhosis.

In September 2025, Galectin Therapeutics reported Q2 financial results with a reduced net loss of $7.6 million, ending the quarter with $13.8 million in cash and securing an additional $10 million credit line. This financial stability extends their operational runway into mid-2026, supporting the advancement of their clinical programs.

The ongoing NAVIGATE Phase 2/3 trial for belapectin has shown a 49.3% reduction in new varices at the 2 mg/kg dose, along with significant improvements in liver stiffness compared to placebo. With a favorable safety profile and promising clinical results, belapectin has the potential to be a novel therapy for severe liver disease.

Galectin Therapeutics Inc. (GALT) has seen a surge in investor interest, with the stock rising over 7% in the past week and more than 50% in recent months. Their strong clinical trial data and solid financial foundation position them as one of the best penny stocks in biotech, attracting investors looking for growth potential.

While Galectin Therapeutics shows promise as an investment, certain AI stocks may offer greater upside potential and lower downside risk. For those seeking an undervalued AI stock poised to benefit from current trends, a free report on the best short-term AI stock is available for further insight.

Read more at Yahoo Finance: Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials